A L Klochikhin

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Ravindra Uppaluri, Robert I. Haddad, Yungan Tao et al. · New England Journal of Medicine · 2025 · 266 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.

Ravindra Uppaluri, Nancy Y. Lee, William H. Westra et al. · Journal of Clinical Oncology · 2019 · 51 citations

Medicine, Oncology, Pharmacology +17

A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer

Jaume Capdevila, A L Klochikhin, Sophie Leboulleux et al. · Thyroid · 2022 · 18 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11